Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Logitech, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Published 18/03/2024, 09:57
Updated 18/03/2024, 11:40
© Reuters. Logitech, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining by around 100 points on Monday.

Shares of Logitech International S.A. (NASDAQ: LOGI) fell in today’s pre-market trading.

Logitech announced the departure of CFO Chuck Boynton and reaffirmed its 2024 financial outlook.

Logitech International shares declined 4.8% to $90.14in pre-market trading.

Here are some big stocks recording losses in today’s pre-market trading session.

  • B. Riley Financial, Inc. (NASDAQ: RILY) shares dipped 11% to $15.65 pre-market trading. B. Riley Financial failed to file its audited results after the end of extension period.
  • Nanobiotix S.A. (NASDAQ: NBTX) shares tumbled 10.8% to $6.19 in pre-market trading after gaining 10% on Friday.
  • Shift4 Payments, Inc. (NASDAQ: FOUR) dipped 9.1% to $70.50 pre-market trading. The company’s CEO Jared Isaacman said bids from potential contenders failed to sufficiently value the firm, according to Bloomberg News.
  • AlTi Global, Inc. (NASDAQ: ALTI) shares fell 6.7% to $5.90 in pre-market trading. AlTi Global posted a loss of 87 cents per share for the fourth quarter, versus a year-ago loss of 21 cents per share. The company’s quarterly sales came in at $91.71 million.
  • Li Auto Inc. (NASDAQ: LI) fell 5.8% to $35.57 in pre-market trading after gaining around 3% on Friday.
  • Geron Corporation (NASDAQ: GERN) shares declined 5.1% to $3.19 in pre-market trading after jumping 92% on Friday. The company announced that the FDA Oncologic Drugs Advisory Committee voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
  • Sibanye Stillwater Limited (NYSE: SBSW) shares fell 3.8% to $4.35 in pre-market trading.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Now Read This: Investor Sentiment Falls Further, S&P 500 Records Second Weekly Loss

Don’t forget to check out our premarket coverage here

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.